Tarazov P G
Central Research Institute of Roentgeno-Radiology, Ministry of Health of the RF, St. Petersburg.
Vopr Onkol. 2000;46(5):561-6.
Transcatheter hepatic artery chemoembolization (THACE) for inoperable colorectal carcinoma metastatic to the liver has been evaluated. Cytostatics were given to 67 patients (Dioxadet 10-30 mg--23; Doxorubicin 40-100 mg--44) in 183 courses using oil and gelatin sponge (1986-1999). Response to treatment (partial decrease in tumor size or growth stabilization) for Dioxadet and Doxorubicin was 47 and 66%, respectively; major complications--17% (fatalities--9%) and 11%, respectively. Mean survival rate was 10 and 11 months; median survival--9 and 10 months, respectively. Repeated THACE-assisted treatment with Doxorubicin was followed by mean survival of 14 months, median--12; one-year survival increased by 77%. THACE-mediated treatment with Dioxadet proved less effective and involved more complications. Further research in modifications of endovascular intervention is needed, including their combinations with systemic treatment of metastatic cancer of the liver.
已对经导管肝动脉化疗栓塞术（THACE）用于无法手术的转移性肝癌进行了评估。1986年至1999年期间，共183个疗程对67例患者（23例使用二氯二乙胺10 - 30毫克，44例使用阿霉素40 - 100毫克）使用油和明胶海绵进行了治疗。二氯二乙胺和阿霉素的治疗反应（肿瘤大小部分缩小或生长稳定）分别为47%和66%；主要并发症分别为17%（死亡率为9%）和11%。平均生存率分别为10个月和11个月；中位生存期分别为9个月和10个月。阿霉素重复进行THACE辅助治疗后的平均生存期为14个月，中位生存期为12个月；一年生存率提高了77%。二氯二乙胺介导的THACE治疗效果较差且并发症更多。需要对血管内介入治疗的改进进行进一步研究，包括其与肝转移癌全身治疗的联合应用。
